Arcturus Therapeutics News and Activities
Presence
Arcturus Therapeutics develops RNA-based medicines and vaccines. Its products and services include drug candidates, vaccine technology, and delivery systems for pharmaceutical partners, healthcare markets, and patients with infectious and rare diseases.
Arcturus Therapeutics products and services overview:
- RNA medicines
- Vaccines
- Drug delivery systems
- Genetic medicines
- Research partnerships
Revenue: ~$166 million
Employees: 180
Headquarters: San Diego, United States (USA)
Arcturus Therapeutics is one of the...
Arcturus Therapeutics is a company listed under the stock ticker ARCT (US).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at Arcturus Therapeutics
- Joseph Payne, Director, President and Chief Executive Officer
- Magda Marquet, Director
- Jing Marantz, Director
Popular executive movements at Arcturus Therapeutics
- Dina Berdieva, Senior Vice President, Operations, has left the company (posted on June 22 2026).
- Dennis Mulroy has joined the company as Chief Financial Officer (posted on June 22 2026).
- Andrew Sassine, Chief Financial Officer and Director, will leave the company on Dec. 31, 2025 (posted on December 16 2025).
Create your alert
to follow the executive moves at Arcturus Therapeutics.
Biotechnology
Arcturus Therapeutics has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
- RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
- Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Popular contacts in Biotechnology
News
Press releases by Arcturus Therapeutics
- Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Arcturus Therapeutics, Inc.
- Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study | Arcturus Therapeutics, Inc.
- Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update | Arcturus Therapeutics, Inc.
- View more press releases Close
Social media about Arcturus Therapeutics
- Arcturus Therapeutics on Wikipedia, Google News & Yahoo Finance
- Arcturus Therapeutics on LinkedIn, X (Twitter) & YouTube
